Overview

Update
Total Equity Funding
$83.92M in 4 Rounds from 10 Investors
Most Recent Funding
$40M Series D on July 15, 2015
Headquarters:
San Diego, CA
Description:
AnaptysBio develops antibody therapeutics based on somatic hypermutation.
Founders:
Categories:
Therapeutics, Health Care, Biotechnology
Website:
http://www.anaptysbio.com
Social:

Company Details

Update

AnaptysBio is a privately-held therapeutic antibody product company and the leader in the use of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies to fight disease. The Company's SHM-Platform™ utilizes the key components of SHM and other techniques to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection – a process that has been referred to as “naturalizing” antibodies. This versatile platform can be used both to discover and optimize antibodies directed at specific disease targets and also affinity mature existing antibodies to improve their binding properties. In addition to providing a more powerful approach to antibody discovery and protein optimization, it addresses a growing void in the therapeutic antibody field due to a string of acquisitions and licensing deals that have reduced the availability of many technologies.

Funding Rounds (5) - $85.95M

Update
DateAmount / RoundValuationLead InvestorInvestors
Jul, 2015$40M / Series D5
Aug, 2013$2.02M / Debt Financing0
Oct, 2011$8.02M / Venture0
Nov, 2007$33.9M / Series B6
Jul, 2006$2M / Series A1

Current Team (2)

Update

Board Members and Advisors (3)

Update

Offices/Locations (1)

Update
  • Office

    10835 Road To The Cure

    Suite 100

    San Diego, CA 92121

    USA

Past Team (3)

Update

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos